UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

Clinical cancer research, 2006-09, Vol.12 (17), p.5165-5173

2006

Volltextzugriff (PDF)

A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry

Leukemia & lymphoma, 2022-11, Vol.63 (13), p.3165-3174

2022

Volltextzugriff (PDF)

High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes

Haematologica (Roma), 2023-02, Vol.108 (2), p.532-542

2023

Volltextzugriff (PDF)

Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier?

Journal of clinical oncology, 2003-04, Vol.21 (8), p.1618-1623

2003

Volltextzugriff (PDF)

Cytarabine and daunorubicin for the treatment of acute myeloid leukemia

Expert opinion on pharmacotherapy, 2017-11, Vol.18 (16), p.1765-1780

2017

Volltextzugriff (PDF)

Predictors of outcome in adults with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-based regimen

Leukemia research, 2014-05, Vol.38 (5), p.532-536

2014

Volltextzugriff (PDF)

Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML

Blood advances, 2019-08, Vol.3 (15), p.2307-2311

2019

Volltextzugriff (PDF)

Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimen

Leukemia research, 2012-12, Vol.36 (12), p.1517-1520

2012

Volltextzugriff (PDF)

Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies

Clinical cancer research, 2005-09, Vol.11 (18), p.6615-6624

2005

Volltextzugriff (PDF)

High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission

Leukemia research, 2013-05, Vol.37 (5), p.556-560

2013

Volltextzugriff (PDF)

Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia

Expert opinion on investigational drugs, 2019-10, Vol.28 (10), p.835-849

2019

Volltextzugriff (PDF)

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial

The lancet oncology, 2017-10, Vol.18 (10), p.1317-1326

2017

Volltextzugriff (PDF)

Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol

Leukemia, 2024-04, Vol.38 (4), p.912-913

2024

Volltextzugriff (PDF)

Patient‐related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS‐CAN prospective study

British journal of haematology, 2016-07, Vol.174 (1), p.88-101

2016

Volltextzugriff (PDF)

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

Cancer, 2018-01, Vol.124 (2), p.325-334

2018

Volltextzugriff (PDF)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)

Current oncology (Toronto), 2023-06, Vol.30 (7), p.6177-6196

2023

Volltextzugriff (PDF)

Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m IDH1 ) acute myeloid leukemia (AML)

Leukemia & lymphoma, 2024-08, Vol.65 (8), p.1145-1152

2024

Volltextzugriff (PDF)

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML

Blood, 2007-04, Vol.109 (8), p.3509-3512

2007

Volltextzugriff (PDF)

Revised 15-item MDS-specific frailty scale maintains prognostic potential

Leukemia, 2020-12, Vol.34 (12), p.3434-3438

2020

Volltextzugriff (PDF)

NKIAMRE, a novel conserved CDC2-related kinase with features of both mitogen-activated protein kinases and cyclin-dependent kinases

Biochemical and biophysical research communications, 2003-09, Vol.308 (4), p.784-792

2003

Volltextzugriff (PDF)

The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry

Leukemia & lymphoma, 2023-02, Vol.64 (3), p.651-661

2023

Volltextzugriff (PDF)

1 – 25 von 142

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(141)
Mit Volltextzugriff
(127)

Publikationsform

Artikel
(141)
Buchkapitel
(1)

Sprache

Englisch
(142)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(62)
Science & Technology
(62)
Humans
(56)
Hematology
(43)
Female
(36)
Male
(36)
Oncology
(34)
Aged
(32)
Middle Aged
(32)
Adult
(23)
Treatment Outcome
(23)
Aged, 80 And Over
(17)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(16)
Leukemia, Myeloid, Acute - Drug Therapy
(16)
Acute Myeloid Leukemia
(14)
Chemotherapy
(14)
Prognosis
(13)
Retrospective Studies
(12)
Antineoplastic Agents - Therapeutic Use
(11)
Leukemia
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry

High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes

Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier?

Cytarabine and daunorubicin for the treatment of acute myeloid leukemia

Predictors of outcome in adults with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-based regimen

Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML

Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimen

Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies

High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission

Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial

Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol

Patient‐related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS‐CAN prospective study

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)

Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m IDH1 ) acute myeloid leukemia (AML)

Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient‐related factors and measuring from time of first red blood cell transfusion dependence: an MDS‐CAN analysis

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML

Revised 15-item MDS-specific frailty scale maintains prognostic potential

NKIAMRE, a novel conserved CDC2-related kinase with features of both mitogen-activated protein kinases and cyclin-dependent kinases

The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry

Suchergebnisse filtern